Stock Analiz

Xenetic Biosciences, Inc. XBIO

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$1.66Market cap $4M
Open the interactive analysis →

Xenetic Biosciences, Inc. (XBIO) is a healthcare company listed in the US with a market value of about $4M. In the twelve months to September 30, 2026 it had revenue of $3M and net income of -$4M, a net margin of -123.7%.

Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 47% a year, a 5-year average ROIC of -37%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 19% below the current price.

About Xenetic Biosciences

Xenetic Biosciences is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $3M in 2016 to $3M in 2025, a decline of about 0.1% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 20% over three years (dilution for shareholders). It spends 103% of revenue on research and development.

Score: 2.0 / 5

Value0/5
Future growth4/5
Track record1/5
Financial health4/5
Shareholder returns1/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S1.3
P/B0.9
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−19%

Growth and quality

Revenue growth (1 yr)19.0%
Revenue growth (5 yrs, per year)46.8%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-256.3%
ROIC (5-yr avg.)-37.1%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$3M$3M$3M$3M$2M$1M$436942$17066$0$8M$3M
Net income-$4M-$3M-$4M-$4M-$7M-$6M-$11M-$13M-$7M-$4M-$54M
Free cash flow————————-$6M$1M-$9M
EPS (diluted)$-1.55$-1.58$-2.57$-2.71$-4.61$-5.50$-17.00$-63.30$-96.60$-49.19$-940.67
Net margin-123.7%-90.1%-158.4%-162.8%-383.9%-486.4%-2493.1%-74856.6%—-47.4%-1806.9%
ROIC—-30.3%-55.3%-36.4%-38.9%-24.7%-89.7%-59.1%-58.0%-19.7%-231.7%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Xenetic Biosciences stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 19% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Xenetic Biosciences pay a dividend?

Not currently.

Is Xenetic Biosciences a good stock to buy?

We do not give buy or sell advice. Xenetic Biosciences scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.